STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 21,155 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 21,155 shares of the firm’s stock in a transaction on Tuesday, January 14th. The shares were acquired at an average cost of $21.46 per share, for a total transaction of $453,986.30. Following the completion of the acquisition, the insider now owns 10,869,786 shares of the company’s stock, valued at approximately $233,265,607.56. This trade represents a 0.20 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.50 per share, with a total value of $176,751.50.
• On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The shares were bought at an average cost of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Stock Up 2.0 %

Shares of NASDAQ:STAA opened at $22.29 on Friday. The firm has a fifty day simple moving average of $25.38 and a two-hundred day simple moving average of $31.83. STAAR Surgical has a 52 week low of $21.13 and a 52 week high of $52.68. The stock has a market capitalization of $1.10 billion, a P/E ratio of 50.66 and a beta of 0.63.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in STAA. Arcadia Investment Management Corp MI purchased a new stake in STAAR Surgical during the third quarter valued at approximately $37,000. Quarry LP bought a new position in shares of STAAR Surgical during the 3rd quarter valued at approximately $50,000. Quest Partners LLC purchased a new stake in STAAR Surgical during the 3rd quarter valued at $128,000. Canada Pension Plan Investment Board bought a new stake in STAAR Surgical in the second quarter worth $129,000. Finally, Van ECK Associates Corp boosted its stake in STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock worth $129,000 after buying an additional 393 shares during the period. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on STAA. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Canaccord Genuity Group decreased their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a research note on Monday, December 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, STAAR Surgical has an average rating of “Hold” and an average target price of $42.83.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.